文献速递前列腺癌

多参数MRI时代初始省略活检后临床显著性前列腺癌的检出

Detection of clinically significant prostate cancer following initial omission of biopsy in multiparametric MRI era.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2024-06-10

本研究纳入2018年3月至2021年6月PSA 2-20 ng/mL、初始多参数前列腺MRI为PIRADS 1-3且未选择活检的活检初治男性,分析重复MRI、后续活检及临床显著性前列腺癌(csPCa,Grade Group ≥2)检出的相关因素。1494例中31%(463/1494)未行活检,csPCa无诊断生存率为97.6%(326/334),中位随访23.1个月,后续csPCa检出率为2.4%。

要点

  • PSA密度≤0.1、前列腺健康指数(PHI)<55及PIRADS 1-2与省略前列腺活检相关。
  • 未活检者csPCa无诊断生存率为97.6%(326/334),中位随访23.1个月(IQR 15.1-34.6个月)。
  • 后续确诊csPCa的8例在重复mpMRI时均为PIRADS 4-5。

核心结论

  • 初始mpMRI后未行活检的患者后续csPCa检出率低,为2.4%。
  • 在初始PHI、PSAD和mpMRI令人放心的情况下省略活检,结合随访中令人放心的血清生物标志物和针对性mpMRI,似乎是安全的。

研究设计与样本

  • 研究为对活检初治男性的分析,纳入PSA 2-20 ng/mL、2018年3月至2021年6月行初始mpMRI为PIRADS 1-3、未选择活检且随访≥6个月的男性。
  • 采用单变量和多变量logistic回归分析与重复mpMRI、进展至活检及后续csPCa检出相关的因素。

主要发现

  • 1494例男性中31%(463/1494)未行前列腺活检。
  • PSA密度≤0.1、PHI<55和PIRADS 1-2与省略前列腺活检相关。
  • csPCa无诊断生存率为97.6%(326/334),中位随访23.1个月(IQR 15.1-34.6个月)。
  • 黑人种族、PSA、PHI、PSA密度及PSA和PHI速度是接受重复mpMRI(15.6%,52/334)和后续活检(8.4%,28/334)的显著预测因素。
  • 8例随后诊断为csPCa(7例经前列腺活检,1例经钬激光前列腺剜除术偶然发现)。

关键数值与推荐

  • 后续csPCa检出率为2.4%。
  • 所有确诊csPCa的患者在重复mpMRI时均为PIRADS 4-5。

临床怎么用

  • 作者认为,在初始PHI、PSAD和mpMRI令人放心的情况下省略活检,并结合随访中令人放心的血清生物标志物和针对性mpMRI,似乎是安全的。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Multiparametric prostate MRI (mpMRI) is being increasingly adopted for work-up of prostate cancer. For patients selected to omit biopsy, we identified factors associated with repeat MRI, eventual prostate biopsy, and subsequent detection of clinically significant prostate cancer (csPCa, Grade Group ≥2). METHODS: We identified biopsy-naïve men presenting with PSA 2-20 ng/mL (March 2018-June 2021) undergoing initial mpMRI with PIRADS 1-3 lesions who were not selected for biopsy with ≥6 months follow-up. We examined factors associated with repeat mpMRI, progression to biopsy, and subsequent detection of csPCa with univariable and multivariable logistic regression. RESULTS: Of 1494 men, 31% (463/1494) did not pursue biopsy. PSA density (PSAD) ≤ 0.1, prostate health index (PHI) < 55, and PIRADS 1-2 were associated with omission of prostate biopsy. csPCa diagnosis-free survival was 97.6% (326/334) with median follow up of 23.1 months (IQR 15.1-34.6 months). Black race, PSA, PHI, PSA density, and PSA and PHI velocity were significant predictors of undergoing repeat mpMRI (15.6%, 52/334) and subsequent biopsy (8.4%, 28/334). 8 men were subsequently diagnosed with csPCa (N = 7 on prostate biopsy; N = 1 incidentally on holmium enucleation of prostate). All patients diagnosed with csPCa had PIRADS 4-5 on repeat mpMRI. CONCLUSIONS: The subsequent detection rate of csPCa among patients not initially biopsied after mpMRI was low at 2.4%. Decisions to omit biopsy after initial reassuring PHI, PSAD, and mpMRI appear safe with subsequent reassuring serum biomarkers and for cause mpMRI during follow-up.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Li EV, Busza AM, Siddiqui MR, et al. Detection of clinically significant prostate cancer following initial omission of biopsy in multiparametric MRI era. Prostate Cancer Prostatic Dis. 2024. PMID: 38858446. doi:10.1038/s41391-024-00853-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。